PTC Therapeutics competitorsClear all

PTC Therapeutics's top competitors include GT Biopharma, MyoKardia, Otonomy and Flexion Therapeutics.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of small-molecule drugs.
GT Biopharma
GT Biopharma
GT Biopharma (formerly Oxis International) is engaged in the development of immunotherapies for cancer treatment.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Flexion Therapeutics
Flexion Therapeutics
Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Founding Date
Founding Date
1998
Founding Date
1965
Founding Date
2012
Founding Date
2008
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
South Plainfield, US HQ
Locations
Tampa, US HQ
Beverly Hills, US
Locations
South San Francisco, US HQ
Brisbane, US
Locations
San Diego, US HQ
Locations
Burlington, US HQ
Employees
Employees
75448% increase
Employees
340% decrease
Employees
23542% increase
Employees
49
Employees
2728% increase
Valuation ($)
Valuation ($)
4.7 b
Valuation ($)
41.7 m
Valuation ($)
12 b
Valuation ($)
250.8 m
Valuation ($)
645.2 m
Twitter followers
Twitter followers
1.1 k
Twitter followers
63
Twitter followers
1.2 k
Twitter followers
214
Twitter followers
885
Number of tweets (last 30 days)
Number of tweets (last 30 days)
17
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
10.8
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
3.7
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
94.12%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
211454
Alexa Website Rank
342819
Alexa Website Rank
239431
Alexa Website Rank
339305
Alexa Website Rank
358736
Employee Rating
Employee Rating
3
Employee Rating
N/A
Employee Rating
4.2
Employee Rating
4.3
Employee Rating
3.9

Financial

Revenue (est.)
Revenue (est.)
$307m (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
$73m (FY, 2019)
Cost of goods
Cost of goods
$12.1m (FY, 2019)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$912k (FY, 2019)
Cost of goods
$10m (FY, 2019)
Gross profit
Gross profit
$294.8m (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Gross profit
($312k) (FY, 2019)
Gross profit
$63m (FY, 2019)
Net income
Net income
($251.6m) (FY, 2019)
Net income
($38.6m) (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
($149.8m) (FY, 2019)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
2 (FY, 2016)
Patents Issued
N/A
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Pending
Patents Pending
N/A
Patents Pending
2 (FY, 2016)
Patents Pending
N/A
Patents Pending
115 (FY, 2016)
Patents Pending
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
3 (FY, 2018)
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.4m
Total funding raised
$ 98m
Total funding raised
$ 153.4m
Total funding raised
$ 62m
For sources of this data, please see the company profile

View company profiles

GT Biopharma
HQ
Tampa, US
Employees
3↓ 40% decrease

GT Biopharma (formerly Oxis International) is engaged in the development of immunotherapies for cancer treatment.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Flexion Therapeutics
HQ
Burlington, US
Employees
272↑ 8% increase

Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.

View company